Publications

1. Ross SD & Schachter RK. A randomized comparison of three conventional modes of treatment of psoriasis of the scalp. Cutis 1981; 28: 438-9.
2. Wilson JJ, Zahn CA, Ross SD, and Newman H. Association of embolic stroke in pregnancy with the lupus anticoagulant. J Rep Med 1986; 31: 725-8.
3. Ross S and Osband ME. Autolymphocyte therapy: an outpatient, low toxicity approach to adoptive immunotherapy. Cancer Metastasis. 1989; Springer-Verlag, Heidelberg, 186-91.
4. Krane RJ, Carpinito GA, Ross SD, Lavin PT, Osband ME. Treatment of metastatic renal cell carcinoma with autolymphocyte therapy: A low toxicity outpatient approach to adoptive immunotherapy without use of in vivo interleukin-2. Urology 1990; 35: 417-22.
5. Osband ME and Ross SD. Problems in the investigational study and clinical use of cancer immunotherapy. Immunol Today 1990; 11: 193-5.
6. Osband ME, Lavin PT, Babayan RK, Graham S, Lamm DL, Parker B, Sawczuk I, Ross S, Krane RJ. Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal cell carcinoma. Lancet 1990; 335: 994-8.
7. Lavin PT, Maar R, Franklin M, Ross S, Martin J, and Osband ME. Autolymphocyte therapy for metastatic renal cell carcinoma: initial clinical results from 335 patients treated in a multisite clinical practice. Trans Proc 1992; 24: 3057-62.
8. Graham S, Babayan RK, Lamm DL, Sawczuk I, Ross SD, Lavin PT, Osband ME, and Krane RJ. The use of ex vivo activated memory T cells (autolymphocyte therapy) in the treatment of metastatic renal cell carcinoma: final results from a randomized, controlled, multisite study. Sem Urolog 1993; 11:27-34.
9. Ross S, Liu V, Abulafia R, Hogan, and Osband M. Adoptive immunotherapy of hormone refractory, stage D2 prostate cancer using ex vivo activated autologous T-cells (autolymphocyte therapy): results from a pilot study. Biotech Ther 1993; 4: 197-211.
10. Krane RJ, Ross SD, Babbitt B, Lavin PT, Martin J, Goodwin J, Caplan B, Zhang J and Osband ME. The scientific and clinical results of ex vivo activated T cells for metastatic renal cell carcinoma in over 500 human patients. Cell Trans 1994; 3 (S1): 51.
11. Gold JE, Ross SD, Krellenstein DJ, LaRosa F, Malamud SC, Osband ME. Adoptive transfer of ex vivo activated memory T cells with or without cyclophosphamide for advanced metastatic melanoma: results in 36 patients. Eur J Cancer 1995.
12. Seaman E, Ross S, and Sawczuk I. High incidence of asymptomatic brain lesions in metastatic renal cell carcinoma. J Neuro-Oncology 1995; 23: 253-256.
13. Stason WB, Whiting G, Schmid C, Niedzwiecki D, Luo D, Caubet J-F, Cory D, Sheinhait I, Ross SD, and Chalmers TC. Searching for Signals: Mortality and cardiovascular events in published randomized control trials of nifedipine in ischemic heart disease and hypertension. J Hypertension 1996: 14 (suppl2) S5-S7.
14. Caubet JF, Stason W, Bishop D, Ross SD. Sample sizes and withdrawals in clinical trials. Lancet 1996: 348; 895.
15. Ross SD. The CONSORT Statement. JAMA 1996 276: 1877.
16. Caubet J-F, Tosteson TD, Dong EW, Naylon E, Whiting GW, Ernstoff MS, and Ross S. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using non-steroidal anti-androgens. Urology 1997: 49: 1-9.
17. Tunis S, Sheinhait IA, Schmid C, Bishop DJ, Ross SD. The efficacy of lansoprazole compared to histamine-2 receptor antagonists in healing gastric ulcers: a meta-analysis. Clinical Therapeutics 1997; 19: 743-757.
18. Dong EW, Connelly JE, Borden SP, Yorzyk W, Passov DG, Kupelnick B, Luo D, Ross SD. A systematic review and meta-analysis of the incidence of cancer in randomized, controlled trials of verapamil. Pharmacotherapy 1997; 17: 1210-1219.
19. Allen IE, Kupelnick B, Kumashiro M, Arellano FM, Mohanty N, Ross SD. Risk of serious adverse events in hypertensive patients receiving isradipine: a meta-analysis. Journal of Human Hypertension 1997; 11:743-751.
20. Ross SD. The role of systematic reviews in pharmacovigilance: a case study of GM-CSF in AIDS. DIA Journal 1998; 32: 639-647.
21. Allen IE, Kupelnick B, Luo D, Kumashiro M, Wollin M, Ross SD. Efficacy of Interleukin-2 in the treatment of metastatic melanoma – systematic review and meta-analysis. Cancer Therapeutics1998; 1; 168-173.
22. Ross SD, DiGeorge,McDOnnell N, Connelly JE. Safety of GM-CSF in patients with AIDS: a review of the literature. Pharmacotherapy 1998; 18(6): 1290-1297.
23. Ross SD, Allen IE, Harrison KJ, Kvasz M, Connelly J, Sheinhait IA. Systematic Review of the Literature Regarding the Diagnosis of Sleep Apnea. Evidence Report/Technology Assessment No.2. (Prepared by MetaWorks Inc. under Contract No. 290-97-0016.) AHCPR Publication No. 99E-=002. Rockville, MD: Agency for Health Care Policy and Research. December 1998.
24. Stason WB, Whiting G, Schmid C, Niedzwiecki D, Whiting G, Luo D, Caubet J-F, Ross SD, and Chalmers TC. Safety of nifedipine in patients with hypertension: a meta-analysis. Hypertension 1998; 30: 7-14.
25. Allen IE, Connelly J, Luo D, Ross SD. Comparison of conventional Papanicoloau smears and a fluid-based, thin layer system for the detection of abnormal cervical lesions: systematic review and meta-analysis. Prim Care Update Ob Gyns 1998; 5(4):163.
26. Stason WB, Schmid C, Niedzwiecki D, Whiting G, Caubet J-F, Cory D, Luo D, Ross SD, and Chalmers TC. Safety of nifedipine in angina pectoris: a meta-analysis. Hypertension 1999; 33: 24-31.
27. Schmid CH, Ross SD, Whiting G, Cory D, Neil G, Kupelnick B, Chalmers TC. Omeprazole plus antibiotics in the eradication of Helicobacter pylori infection: A meta-analysis of randomized, controlled trials. Am J Therapeutics 1999; 6: 25-36.
28. Bennett CL, Tosteson TD, Schmitt B, Weinberg PD, Ernstoff MS, and Ross SD. Maximum androgen blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine randomized controlled trials and 4,128 patients using flutamide. Prostate Cancer and Prostatic Diseases 1999; 2: 4-8.
29. Ross SD, Luo D, Connelly JE, Smith ME, Korenfelt BM, Bishop D. Clinical outcomes in statin trials: a meta-analysis. Arch Intern Med 1999; 159:1793-1802.
30. Allen IE, Monroe M, Connelly J, Cintron R, Ross SD. Impact of postmenopausal hormone replacement therapy on dental outcomes: Systematic review of the literature and pharmacoeconomic analysis. Managed Care Interface. April 2000.
31. Ross SD, Dong E, Gordon M, Connelly JE, Kvasz M, Iyengar M and Mujais SK. Meta-analysis of outcome studies in end-stage renal disease. Kidney International 2000; 57: S28- S38.
32. Kvasc M , Allen IE, Gordon MJ, Ro EY, Estok R, Olkin I, and Ross SD. Adverse drug reactions in hospitalized patients: A critique of a meta-analysis. Medscape General Medicine, April 2000.
33. Ross SD, Allen IE, Harrison KJ, Kvasz M, Connelly J, Sheinhait IA. Systematic Review of the Literature Regarding the Diagnosis of Sleep Apnea. Sleep 2000; 23: 519-532.
34. Ross SD, Allen IE, Harrison KJ, et al. Systematic review of the literature regarding the diagnosis of sleep apnea. ACP Journal Club. 2000 Mar-Apr; 132-69.
35. Borden SP, Monroe MM, Kupelnick B, Connelly JE, Doyle D, Ross SD, and Allen IE. A systematic review of interferon alpha in the treatment of non-Hodgkin’s lymphoma. J Immunotherapy 2001; 1: 58-65..
36. Ross SD. Drug related adverse events: A readers’ guide to assessing literature reviews and meta-analyses. Archives of Internal Medicine 2001; 161: 1041-1046.
37. Chadbourne E. Zhang S, Gordon MJ, Ro EY, Ross SD. Clinical outcomes in reduction mammaplasty: A systematic review and meta-analysis of published studies. Mayo Clinic Proceedings 2001; 76:503-510.
38. Ross SD, Nalysnyk L, Zhang S, et al. Discontinuation of antihypertensive agents due to adverse events: a systematic review and meta-analysis. Pharmacotherapy 2001; 21 (8): 940-953.
39. Zilberberg MD, Levine C, Komaroff E, Guldin M, Gordon MJ, Ross SD. "Clinical uses of gamma-linolenic acid: A systematic review of the literature," In: Huang YS and Ziboh VA, eds. Gamma-linolenic acid: Recent advances in biotechnology and clinical applications. AOCS Press, Champaign, IL, 2001. pp 90-104.
40. Ross, S. Down with fat , dumb, and happy! bmj.com/cgi/eletters/322/7286/569#14318, 7 May 2001.
41. Allen IE, Ross, SD, Borden SP, Monroe M, Kupelnick B, Connelly J, Ozer H. Meta-Analysis to Assess the Efficacy of Interferon-alpha in Patients with Follicular Non-Hodgkin’s Lymphoma. Journal of Immunotherapy 2001; 24(1):58-65.
42. Ross S, Estok R, Chopra S, French J. Management of Newly Diagnosed Patients with Epilepsy: A Systematic Review of the Literature. Evidence Report/Technology Assessment No.39. (Prepared by MetaWorks Inc. under Contract No. 290-97-0016.) AHRQ Publication No. 01-E038. Rockville, MD. February 2001.
43. Levine C, Armstrong k, Chopra S, Estok R, Zhang S, Ross S. Diagnosis and Management of Specific Breast Abnormalities. Evidence Report/Technology Assessment No.33. (Prepared by MetaWorks Inc. under Contract No. 290-97-0016.) AHRQ Publication No. 01-E046. Rockville, MD. April 2001.
44. Edwards B, Silcocks P, Ross SD. Pharmacoepidemiology. Chapter 2, of Pharmacovigilance: Effective Safety Surveillance Strategies. Scrip Reports April 2002.
45. Faich G.; Allen I.E.; Ross S.D.; Lefkowith J.B. Lack of association of celecoxib with an increased risk of thromboembolic events. J Amer Coll of Card 2002; 39: 271.
46. Nalysnyk L, Fahrbach K, Reynolds MW, Zhao SZ, Ross S. Adverse events in CABG trials: A systematic review and analysis. Heart 2003; 89:767-772.
47. 47. Levine C. Estok R, Stone L, Fahrbach K, Ross SD. Systematic review of the Current Literature Related to Disability and Chronic Fatigue Syndrome. Evidence Report/ Technology Assessment No. 66 (Prepared by MetaWorks Inc. under Contract No. 290-97-0016) AHRQ Publication No. 03-E007, Rockville MD. December 2002.
48. Klawansky S, Komaroff E, Cavanaugh PF, Mitchell DY, Gordon MJ, Connelly JE, and Ross SD. The relationship between age, renal function, and bone mineral density in the US population. Osteoporosis International 2003; 14: 570-576.
49. Levine C. Estok R, Fahrbach K, Ross SD. Diagnosis and Treatment of Parkinson's Disease: A Systematic Review of the Literature. Summary, Evidence Report/Technology Assessment: Number 57. (prepared by MetaWorks Inc. under Contract No. 290-97-0016) AHRQ Publication No. 03-E039, Rockville, MD.June 2003.
50. Ross SD Fahrbach K, Frame D, Scheye R, Connelly JE, Glaspy J. The effect of anemia treatment on selected health-related quality-of-life domains: A systematic review. Clinical Therapeutics. 2003; 25:1786-1805.
51. Ross SD, Estok R, Frame D, Stone L, Ludensky V, Levine C. Disability and Chronic Fatigue Syndrome: A focus on function. Arch Intern Med 2004; 164: 1098-1107.
52. Ross SD, Estok R, Chopra S, French J. Management of newly diagnosed patients with epilepsy: A systematic review of the literature. Am Fam Phys 2004; 70: 824-828.
53. Ross S, Estok RP, Armstrong K, Levine C. Should risk factors for breast cancer influence the evaluation of breast abrnomalities: A systematic review of the literature. Am Fam Phys 2004; 70: 35-37.
54. Nalysnyk L, Fahrbach K, Reynolds MW, Zhao SZ, Ross S. Adverse Events in Coronary Artery Bypass Graft (CABG) trials: A Systematic Review and Analysis. Heart 2003; 89(7):767-72.
55. Ross S. Trends in the risks and benefits to patients with cancer in phase 1 clinical trials. [Letter] JAMA 2005; 293:795.
56. Frame D. Ross SD. Systematic review methods: Becoming less dependent on "the coffee queue" . [letter] BMJ 2005. (http://bmj.bmjjournals.com/cgi/eletters/331/7524/1064)
57. Fahrbach K, Sledge I, Cella K, Linz H, Ross SD. A comparison of the accuracy of two minimally invasive breast biopsy methods: a systematic literature review and meta-analysis. Archives of Obstetrics and Gynecology 2006; 274: 63-73.
58. Ross SD, Allen IE, Seaman C, Sercus B. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review and meta-analysis. Clinical Therapeutics 2006; 28: 801-831.
59. Ross SD, Allen IE, Probst C, Sercus B, Crean S, Ranganathan G. Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis. Oncologist 2007; 12: 1264-1273.
    

Abstracts

1. Ross S, Osband ME. Treatment of metastatic renal cell carcinoma (RCC) with autolymphocyte therapy: serum levels of interleukin-2 receptor (sIL2R) and immunosuppressive acidic protein (IAP) predict survival . CIS, 1988.
2. Seder RH, Smith JW, Ross SD, Osband ME. Apheresis kinetics of various serum suppressor factors in cancer patients receiving autolymphocyte therapy (ALT). American Society for Apheresis/Society of Hemapheresis Specialists, 1989.
3. Ross S, Osband M, Krane R, and Lavin P. Prolonged survival in patients with metastatic renal cell carcinoma (RCC) treated with autolymphocyte therapy (ALT): A low toxicity outpatient approach to adoptive immunotherapy without interleukin-2. ASCO, 1989.
4. Ross S, Osband M. Treatment of metastatic renal cell carcinoma (RCC) with autolymphocyte therapy: correlation between survival and the number of infused lymphocytes. FASEB, 1989.
5. Ross SD, Lavin PT, Berg JD, Osband ME. Treatment of renal cell carcinoma with autolymphocyte therapy: an outpatient low toxicity approach to adoptive immunotherapy. CIS, 1989.
6. Ross SD, Lavin PT, Osband ME. Treatment of renal cell carcinoma with autolymphocyte therapy: an outpatient, low toxicity approach to adoptive immunotherapy. SBT, 1989.
7. Ross SD, Lavin PT, Krane RJ, and Osband ME. Autolymphocyte therapy of metastatic renal cell carcinoma results in significant survival prolongation with good quality of life: results of a randomized, controlled, multi-site clinical study. ASBMB/AAI, 1990.
8. Krane RJ, Babayan RK, Graham SD, Lamm DL, Ross SD, Sawczuk IS, Lavin PT, and Osband ME. Treatment of stage IV renal cell carcinoma with autolymphocyte therapy: an outpatient, low toxicity approach to adoptive immunotherapy. AUA, 1990.
9. Pappas PC, Lavin PT, Ross SD, Osband ME. Serious deficiencies in the reporting of cancer clinical trials: do physicians have sufficient data to make treatment decisions? AFCR, 1991.
10. Osband ME, Ross SD, Celis E, Lavin PT, and Krane RJ. Autolymphocyte therapy for metastatic renal cell carcinoma prolongs survival with only minimal toxicity: final results from a randomized clinical trial. AFCR, 1991.
11. Osband M, Lavin P, Ross S, and Krane R. Further evidence for the clinical efficacy of autolymphocyte therapy (ALT) in renal cell carcinoma (RCC) based upon differential survival while on and off therapy. AACR, 1991.
12. Krane RJ, Lavin PT, Babayan RK, Graham SD, Lamm DL, Parker B, Sawzcuk I, Ross SD, Osband ME. Autolymphocyte therapy for metastatic renal cell carcinoma significantly prolongs survival with minimal toxicity: Final results from a randomized, controlled multi-site study. AUA, 1991.
13. Osband M, Ross S, Celis, E, Lavin P, and Krane R. Autolymphocyte therapy (ALT) for renal cell carcinoma with minimal toxicity: Final results from a randomized, controlled, multi-site study. ASCO, 1991.
14. Babbitt B, Celis E, Ross S, Bolwerk A, Clark J, Goodwin J, Hamilton D, Hogan C, and Osband M. Treatment of renal cell carcinoma with autolymphocyte therapy using in vitro activated T cells: Immunologic mechanism and description of diagnostic data in treated patients. Cleveland Clinic Symposium, 1991.
15. Ross SD, Lavin PT, Franklin M, and Osband M. Clinical outcome in the treatment of renal cell carcinoma with autolymphocyte therapy (ALT) using in vitro activated T-cells: Updated results from a randomized controlled trial and initial results from an additional 125 patients. Cleveland Clinic Symposium, 1991.
16. Babbitt B, Celis E, Ross S, Bolwerk A, Clark J, Goodwin J, Hamilton D, Hogan C, and Osband M. Treatment of renal cell carcinoma with autolymphocyte therapy using in vitro activated T-cells: Immunologic mechanism and description of diagnostic data in treated patients. SBT, 1991.
17. Ross SD, Lavin PT, Franklin M, Osband M. Clinical outcome in the treatment of renal cell carcinoma with autolymphocyte therapy (ALT) using in vitro activated T-cells: Updated results from a randomized controlled trial and initial results from an additional 125 patients. SBT, 1991.
18. Ross SD, Lavin PT, Franklin M, Osband ME. Clinical outcome in the treatment of renal cell carcinoma with autolymphocyte therapy (ALT) using in vitro activated T-cells. CIS, 1991.
19. Ross SD, Liu V, Abulafia R, Hogan C, and Osband ME. Adoptive immunotherapy of hormone-refractory stage D2 prostate cancer using ex vivo activated autologous T-cells (autolymphocyte therapy): results from a pilot study. AFCR, 1992.
20. Babbitt B, Celis, Ross S, and Osband ME. Treatment of renal cell carcinoma with ex vivo activated T-cells: mechanism and diagnostic data. AACR, 1992.
21. Babbitt B, Celis E, Ross S, Bolwerk A, Clark J, Goodwin J, and Osband M. Immunologic mechanisms in the treatment of renal cell carcinoma (RCC) with autolymphocyte therapy. AUA, 1992.
22. Krane R, Franklin M, Maar R, Copelan H, Ross S, Lavin P, and Osband M. Clinical outcome in the treatment of renal cell carcinoma with autolymphocyte therapy (ALT) using in vitro activated T-cells: analysis of more than 150 treated patients. AUA, 1992.
23. Ross SD, Lavin PT, Martin J, Miesowicz F, and Osband ME. Extended survival of clinically favorable patients with metastatic renal cell carcinoma (RCC) treated with ex vivo activated memory T-cells (autolymphocyte therapy). Keystone Symposium: Cellular Immunity and Immunotherapy of Cancer, 1993.
24. Ross SD and Osband ME. Autolymphocyte therapy (ALT) for disseminated melanoma: results in a pilot study of 26 patients. ASCO, 1993.
25. Ross SD, Lavin PT, Martin J, Miesowicz F, and Osband ME. A statistical model to predict outcome in patients with metastatic renal cell cancer (RCC) treated with autolymphocyte therapy (ALT). AAI/CIS 1993.
26. Ross SD and Chalmers TC. Methodological inadequacies in the assessment of magnetic resonance angiography (MRA) for extracranial carotid disease (ECD). AAMI Cardiovascular Science and Technology Conference. Washington, Dec. 10-12, 1993.
27. Ross SD, Kupelnick B, Chalmers TC. The poor quality of quality research in health care. AMRCC Research Symposium, Washington, May 17-18, 1994.
28. Ross SD and Chalmers TC. Evaluating effectiveness: whither the evidence? ISTAHC Annual Meeting, Baltimore, June 19-22, 1994.
29. Ross SD and Miesowicz F. Final results of a randomized controlled trial (RCT) of long term autolymphocyte therapy (ALT) in patients with metastatic renal cell cancer (mRCC). (SBT) J Immunother 16: 243, 1994.
30. Chalmers TC, Ross SD, Lau, J. Meta-analysis as a scientific discipline. UK Conference on Evidence-based Medicine, October, 1994.
31. Ross SD and Chalmers TC. Meta-analysis in oncology: an under utilized resource in an under-powered field. ISTAHC Annual Meeting, Stockholm, June 1995.
32. Chalmers TC, Ross SD, Neil G, Lau J, Kupelnick B, and Whiting G. A year after the NIH consensus statement on eradication of H. pylori in peptic ulcer disease, how best to do it? American Gastroenterology Association Annual Meeting, San Diego, May 1995.
33. Osband ME, Gold JE, Ross SD, Krellenstein DJ, LaRosa F, Malamud SC. Adoptive transfer of ex vivo activated memory T-cells with or without cyclophosphamide for advanced metastatic melanoma: results in 36 patients. ASCO Proceedings 14: 418, 1995.
34. Caubet J-F, Tosteson TD, Dong EW, Naylon E, Whiting GW, Ernstoff MS, and Ross S. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using non-steroidal anti-androgens. ASCO Proceedings 1996.
35. Allen IE, Kupelnick B, Kumashiro M, Passov D, Huncharek M, Yorzyk W, Dickstein H, Paradise C, Zimmerman R, Wolin M, Ross SD. The combination of chemotherapy with IL2 and aIFN is more active than chemotherapy or immunotherapy alone in patients with metastatic melanoma: a meta-analysis of 7711 patients with metastatic melanoma. ASCO Proceedings 1997.
36. Bloche C, Dong E, Bishop D, Kumasharo M, Ross S, Caubet J-F. MetaHub: A database of clinical trials for drug development programs. Massachusetts Biotechnology Council Annual Meeting Proceedings, 1996.
37. Caubet J-F, Allen IE, Ross S. Clinical program development using meta-analysis. Massachusetts Biotechnology Council Annual Meeting Proceedings, 1996.
38. Ross SD. A proposal for an industry-sponsored clinical trial registry in the United States. ISTAHC Annual Meeting Proceedings. 1996.
39. Schmid CH, Ross SD, Whiting GW, Cory D, Chalmers TC. Omeprazole plus antibiotics in the eradication of H. pylori infection: a meta-regression. EHPSG IXth International Workshop, Copenhagen DK, 1996.
40. Ross SD, Luo D, Connelly JE, Smith ME, Korenfelt BM, Bishop D. Clinical outcomes in statin trials: a meta-analysis. APOR Conference November 1997.
41. Weinberg P, Bennett CL, Tosteson T, Ross S. Is flutamide effective for total androgen blockade (TAB): Results of an updated literature-based meta-analysis. ASCO Proceedings 1998; 17: 427a.
42. Ross SD, Allen IE, Harrison KJ, Kvasz M, Connelly J, Sheinhait IA. Systematic Review of the Literature Regarding the Diagnosis of Sleep Apnea. Amer. Resp. Therapists November 1998.
43. Zilberberg MD, Komaroff E, Trotti A, Gwede C, Epstein J, Bellm LA, Fuchs HJ, Nalysnyk L, Frame D, Ross SD. Incidence and severity of mucositis are associated with significant resource utilization in patients receiving radiotherapy for head and neck cancer: a systematic review of the literature. ASTRO 2000.
44. Chadbourne E, Zhang S, Schmidt C, Gordon M, Ross SD. Meta-analysis of coublie-blind, placebo-controlled trials investigating the efficacy and safety of miglitol in combination with metformin in patients with Type 2 diabetes.American Diabetes Association, Spring 2000.
45. Komaroff E, Wolfinger R, Ross, SD. PharmSUG conference. Seattle, 2000.
46. Jadad AR, Sullivan C, Luo D, Allen IE, Ross SD, Sheinhait IA. Patient preferences for Turbuhaler or pressurized metered dose inhalers (pMDIs) in the treatment of obstructive airway disease: a systematic review. AAAI Annual meeting, San Diego April 2000.
    
47. Ross SD, Paradise T, Connelly JE, Sethi S, Zhang S. A navigable clinical trial database of breast cancer treatment literature: 841 studies to date. ASCO 2000.
48. Ross SD, Klawansky S, Allen IE, et al. Comparison of GPIIb/IIIa receptor inhibitors in patients undergoing percutaneous coronary interventions (PCI): A meta-analysis. European Society of Cardiology August 2000.
49. Ross SD. Using existing information better: data warehouses and meta-analysis in late phase drug development programs. DIA October 2000.
50. Chopra S, Levine C, Nalysnyk, Komaroff E, Ross SD. Evidence-based rheumatology: A systematic review of the theumatoid arthritis literature and a novel CD-ROM database. ACR October 2000.
51. Ross SD, Connelly J, Malcoff A, Kvasz M. A navigable clinical trial database of asthma treatment literature: 255 studies to date. ACAAI November 2000.
52. Ross SD, Klawansky S, Allen IE. Indirect comparisons of drugs using meta-analysis: validation of results. Value in Health 2001; 4: 55.
53. Ross SD. Drug related adverse events: A guide to assessing literature reviews and meta-analyses. DIA/AHRQ Workshop, April 2001.
54. Nalysnyk L, Ross SD. Oral hypoglycemic agents in NIDDM: A systematic literature review and MetaMap database. American Diabetes Association Annual Meeting, April 2001.
55. Ross S, Klawansky S, Allen E. Indirect comparisons of drugs using meta-analysis: validation of results. ISPOR 2001.
56. Levine C, Chopra S, Nalysnyk L, Ludensky V, Ross SD. Evaluation of new treatments for an old disease: a review of the literature on rheumatoid arthritis using a novel CD-ROM database. AMIA, September 2001.
57. Nalysnyk L, Fahrbach K, Reynolds MW, Zhao SZ, Ross S. Adverse events in CABG trials: A systematic review and analysis. Society Cardiovascular Anesthesiologists March 2002.
58. Faich G, Allen IE, Ross SD, Lefkowith JB. Lack of association of celecoxib with an increased risk of thromboembolic events. JACC, March 2002.
59. Nalysnyk L, Fahrbach K, Reynolds MW, Zhao SZ, Ross S. Adverse events in CABG trials: A systematic review of the literature. ISPOR May 2002.
60. Gallagher E, Osequer D, Romvari E, Brinkmann K, Frame D, Ross S. Clinical guidelines for use of erythropoietin in cancer patients: A nursing perspective of barriers and benefits. Oncology Nurses Society Annual Meeting, Spring 2002.
61. Nalysnyk L, McHugh T, Ross S. Glycemic control and socioeconomic bruden in patients with diabetes mellitus: a systematic review of the literature. ADA June 2002.
62. Nalysnyk L, Graham L, Slobodskaya L, Ross S. Glycemic control and socioeconomic burden in patients with diabetes mellitus: a systematic review of the literature. EASD 2002.
63. Nalysnyk L, Blonde L, Cooppan R, Mishra AK, Graham LA, Ross SD. Burden of Inadequate Glycemic Control in Patients with Diabetes: Evidence from a Systematic Review of the Literature. ADA June 2003.
64. Ross S, Frame D, Sethi S, Curtis V, Drielick M. Analysis of Community Patient Data to Assess Use of HER2 protein testing and trastuzumab treatment in breast cancer patients. ASCO 2003.
65. Reynolds MW, Ross SD, Fahrbach K, Frame D, James K. Real-life patient reported outcomes: Data mining of consumer spontaneous reports for two statins. ISPOR2004.
66. Reynolds MW, Nalysnyk L, Fahrback K, Hauch O, Wygant G, Estok R, Frame D, Cella C, Scheye R, Ross SD. Warfarin Anticoagulation and Outcomes in Atrial Fibrillation Patients: A Systematic Review and Meta-Analysis. ISPOR 2004.
67. Ross SD and Reynolds, MW. Use of the FDA spontaneous adverse event reporting system (SAERS), or why your MedWatch reports really do matter. ASCO 2004.
68. Reynolds MW, Ross SD, Fahrbach K, Frame D, James K. Understanding the role of the report source in signal detection analyses. ISPE 2004.
69. Reynolds MW, Ross SD, Fahrbach K, Frame D, Cella K. Understanding the role of the report date in signal detection analyses. ISPE 2004.
70. Scheye R, Frame D, Ross SD. An Online Database of Treatment Trials in Metastatic Melanoma: Use in Clinical Trial Design and Benchmarking Outcomes. International Society for Biological Therapy of Cancer (iSBTc), 2004.
71. Reynolds MW, Nalysnyk L, Kahrbach K, Hauch O, Wygant G, Frame D, Cella C, Scheye R, Ross SD. Warfarin anticoagulation and outcomes in atrial fibrillation patients: A systematic review and meta-analysis. DIA Risk Management Meeting 2004.
72. Frame D, Fahrbach K, Reynolds M, Ross SD. Use of thresholds for safety reporting in clinical trials. ISPOR 2005.
73. Reynolds M & Ross SD. EBM in Drug Development Seminar, DIA June 2005.
74. Ross SD. Clinical Trials Registries and Results Databases. AMIA October 2005.
75. Almasio PL, Cavalletto L, Chemello L, Craxi A, Fahrbach K, Frame D, Ling CY, Mauss S, Poordad FF, Ross SD, Zein NN, Herrine S, Trepo C. Efficacy of PEG-IFN alfa-2b vs. PEG-IFN alfa-2a + ribavirin regimens in treatment-naïve chronic HCV patients: A cumulative meta-analysis of retrospective data from 6 clinic sites. AASLD, November 2005.
76. Almasio PL, Cavalletto L, Chemello L, Craxi A, Fahrbach K, Frame D, Ling CY, Mauss S, Poordad FF, Ross SD, Zein NN, Herrine S, Trepo C. Predictors of SVR in genotype 1 patients with treatment-naïve chronic HCV treated with PEG-IFN alfa-2b vs. PEG-IFN alfa-2a + ribavirin: A hierarchical linear regression analysis of retrospective data from 6 clinic sites. DDW, May 2006.
77. Ross, Fahrbach K, Estok R, Sledge I. Bariatric surgery using Swedish Adjustable Gastric Band or LAP-BAND: An updated systematic review of the literature and meta-analysis. ASBS, May 2006.
78. Ross SD, Allen IE, Seaman C, Sercus B. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review and meta-analysis. MASCC, June 2006.
79. Ross SD, Frame D, Winterkorn A, Fahrbach K. Analyses from routine patient care settings for clinical research purposes. ISPOR May 2007.
80. Luo W, Nordstrom B, Ranganathan G, Linz H, Stokes M, Ross M, Knopf K. Adherence to guidelines for use of erythropoiesis stimulating proteins in patients with chemotherapy-induced anemia: Trends from Electronic Medical Records ISPOR 2007.
81. Ross SD. Using electronic medical records for clinical effectiveness research. ISPOR May 2007.
82. Ross SD. Using electronic medical records for clinical research. DIA June 2007.
83. Luo W, Nordstrom B, Ranganathan G, Fraeman K, Linz H,Stokes M, Knopf K, Ross S. Adherence to guidelines for use of erythropoiesis stimulating proteins in patients with chemotherapy-induced anemia: Trends from Electronic Medical Records. MASCC 2007.
84. Frame D, Ross S. Concordance of study objectives with efficacy findings in metastatic breast cancer (MBC) treatment trials. ASCO 2007.
85. Luo W, Nordstrom B, Ranganathan G, Linz H, Stokes M, Ross M, Knopf K. Adherence to guidelines for use of erythropoiesis stimulating proteins in patients with chemotherapy-induced anemia: Trends from Electronic Medical Records ASCO 2007.